Article Sidebar
Published:
Jan 20, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Inhibitory effect and mechanism of action of tanshinone IIA on human bladder cancer cell J82
Abstract
Purpose: To investigate the therapeutic influence of tanshinone IIA on human bladder cancer cell J82, and the possible signal route involved.
Methods: Cell proliferative potential was measured using MTT assay, while the expressions of associated genes were determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunoblot assays.
Results: Tanshinone IIA decreased J82 cell survival rate by > 42 % and inactivated apoptosis by suppressing PI3K/AKT/mTOR signal route. Moreover, it decreased Bcl-2, but upregulated caspase and Bax (p < 0.05).
Conclusion: The inhibitory effect of TIIA on human bladder cancer suggests that TIIA can be developed into an anti-tumor agent.
